Invention Grant
- Patent Title: Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof
-
Application No.: US15778897Application Date: 2016-11-24
-
Publication No.: US10717753B2Publication Date: 2020-07-21
- Inventor: Yinsheng Zhang , Baomin Liu , Beibei Yang
- Applicant: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Applicant Address: CN Lianyungang
- Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Current Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Current Assignee Address: CN Lianyungang
- Agency: Nixon Peabody LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@a8ebd6
- International Application: PCT/CN2016/107048 WO 20161124
- International Announcement: WO2017/088784 WO 20170601
- Main IPC: C07F9/6558
- IPC: C07F9/6558 ; A61K31/675 ; A61P35/00 ; C07B59/00
Abstract:
The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.
Public/Granted literature
- US20180346498A1 Deuterium-Modified Brigatinib Derivatives, Pharmaceutical Compositions Comprising Same, And Use Thereof Public/Granted day:2018-12-06
Information query
